Navigation Links
Swift Transportation donates more than $15,000 to the Waylon Fund
Date:12/13/2012

PHOENIX, Ariz. Dec. 13, 2012 Swift Charities, the charitable arm of Swift Transportation, today donated $15,262 to The Waylon Jennings Fund for Diabetes Research at the Translational Genomics Research Institute (TGen).

Throughout November Diabetes Awareness Month The Waylon Fund was Swift's "charity of choice." Half of November's proceeds from thousands of driver donations, as well as matching contributions from Phoenix-based Swift, were collected to benefit TGen's diabetes research in the name of country music legend Waylon Jennings.

In a letter to Swift drivers, Jennings' widow, Jessi Colter, urged them to remember her late husband, who died in 2002 of complications from diabetes, a disease that affects nearly 26 million Americans.

"Waylon Jennings was truly one-of-a-kind. Often thought of as an 'outlaw' and a mentor to a new generation of country and rock acts inspired by his spirit and individualism, he was above all someone who stood strong in the face of adversity," Colter said in her letter. "I am so pleased to announce TGen's new partnership with Jerry Moyes, the founder, chairman and CEO of Phoenix-based Swift Transportation. With the help of Swift Charities and Swift drivers from across the country, The Waylon Fund will spur innovative research at TGen to find better treatments for diabetes."

Jim Stone, Executive Director of Swift Charities, said his company's drivers were eager to answer Colter's call to action.

"Diabetes is one of many health issues that needs greater attention, and we at Swift are proud to partner with another Phoenix-based institution, TGen, to advance biomedical research in this critical area," Stone said. "To be able to do that in conjunction with Jessi Colter, and do it in the memory of Waylon Jennings, that is a real honor."

"TGen's research into diabetes will allow physicians to more accurately predict who has the greatest risk of developing Type 2 diabetes and related complications, while also identifying targets for treatment of the disease," said Dr. Johanna DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division.

Dr. DiStefano leads a team of scientists working in five areas of research: diabetes and heart disease, diabetic nephropathy, diabetes and obesity, diabetes and liver disease, and diabetes and individualized treatment strategies.

"TGen is extremely grateful to the Swift Transportation family for supporting The Waylon Fund for Diabetes Research," said Michael Bassoff, President of the TGen Foundation. "This gift from Swift Charities is reflective of the dedication and generosity of Swift employees nationwide who individually contributed to help accelerate TGen's diabetes research."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Jeff Crandall Honored With SAE International Arnold W. Siegel International Transportation Safety Award
2. To spread, nervous system viruses sabotage cell, hijack transportation
3. Plan to turn farm waste into paper earns students $15,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: